Aprea Therapeutics Inc. priced its IPO of 5,666,667 common shares at $15 apiece.
The Boston-based biopharmaceutical company also granted underwriters a 30-day option to buy up to an additional 850,000 common shares.
Gross proceeds are expected to be about $85 million.
The company's common shares will begin trading on the Nasdaq Global Select Market on Oct. 3 under the APRE ticker symbol. The offering is expected to close Oct. 7.
J.P. Morgan, Morgan Stanley and RBC Capital Markets are acting as joint book-running managers for the IPO.
Aprea Therapeutics develops therapies for blood cancers such as myelodysplastic syndromes and acute myeloid leukemia.
